User menu

Landmarks in hormonal therapy for prostate cancer.

Bibliographic reference Tombal, Bertrand ; Crawford, E David. Landmarks in hormonal therapy for prostate cancer.. In: BJU International, Vol. 111, no.3, p. E12-3 (2013)
Permanent URL http://hdl.handle.net/2078.1/125577
  1. Hammerer Peter, Madersbacher Stephan, Landmarks in hormonal therapy for prostate cancer : HORMONAL THERAPY FOR PROSTATE CANCER, 10.1111/j.1464-410x.2012.11431.x
  2. Klotz Laurence, Boccon-Gibod Laurent, Shore Neal D., Andreou Cal, Persson Bo-Eric, Cantor Per, Jensen Jens-Kristian, Olesen Tine Kold, Schröder Fritz H., The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer, 10.1111/j.1464-410x.2008.08183.x
  3. IVERSEN PETER, TYRRELL CHRIS J., KAISARY AMIR V., ANDERSON JOHN B., VAN POPPEL HEIN, TAMMELA TEUVO L.J., CHAMBERLAIN MICHAEL, CARROLL KEVIN, MELEZINEK IVAN, BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP, 10.1016/s0022-5347(05)67032-2
  4. Doehn, I Drugs, 9, 565 (2006)
  5. Mongiat-Artus Pierre, Teillac Pierre, Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer, 10.1517/14656566.5.10.2171
  6. Gittelman Marc, Pommerville Peter J., Persson Bo-Eric, Jensen Jens-Kristian, Olesen Tine Kold, A 1-Year, Open Label, Randomized Phase II Dose Finding Study of Degarelix for the Treatment of Prostate Cancer in North America, 10.1016/j.juro.2008.07.033
  7. Ozono S., Ueda T., Hoshi S., Yamaguchi A., Maeda H., Fukuyama Y., Takeda K., Ohashi Y., Tsukamoto T., Naito S., Akaza H., The Efficacy and Safety of Degarelix, a GnRH Antagonist: A 12-month, Multicentre, Randomized, Maintenance Dose-finding Phase II Study in Japanese Patients with Prostate Cancer, 10.1093/jjco/hys035
  8. Van Poppel Hendrik, Tombal Bertrand, de la Rosette Jean J., Persson Bo-Eric, Jensen Jens-Kristian, Kold Olesen Tine, Degarelix: A Novel Gonadotropin-Releasing Hormone (GnRH) Receptor Blocker—Results from a 1-yr, Multicentre, Randomised, Phase 2 Dosage-Finding Study in the Treatment of Prostate Cancer, 10.1016/j.eururo.2008.04.065
  9. Broqua P., Pharmacological Profile of a New, Potent, and Long-Acting Gonadotropin-Releasing Hormone Antagonist: Degarelix, 10.1124/jpet.301.1.95
  10. Koechling Wolfgang, Hjortkjaer Rolf, Tankó László B., Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples : Histamine release by GnRH antagonists, 10.1111/j.1365-2125.2010.03730.x
  11. European Medicines Agency EU SMPc 28/06/2012 Firmagon - EMEA/H/C/000986 - II/0011 2012 http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000986/WC500023252.pdf
  12. Crawford E. David, Moul Judd W., Shore Neal D., Kold Olesen Tine, Persson Bo-Eric, 670 SWITCHING FROM LEUPROLIDE TO DEGARELIX VS CONTINUOUS DEGARELIX TREATMENT – EFFECTS ON LONG-TERM PROSTATE-SPECIFIC ANTIGEN CONTROL, 10.1016/j.juro.2010.02.1057
  13. Schröder Fritz H., Tombal Bertrand, Miller Kurt, Boccon-Gibod Laurent, Shore Neal D., Crawford E. David, Moul Judd, Olesen Tine Kold, Persson Bo-Eric, Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III study : ALP LEVELS IN PATIENTS WITH PROSTATE CANCER RECEIVING DEGARELIX OR LEUPROLIDE, 10.1111/j.1464-410x.2009.08981.x
  14. Tombal Bertrand, Miller Kurt, Boccon-Gibod Laurent, Schröder Fritz, Shore Neal, Crawford E. David, Moul Judd, Jensen Jens-Kristian, Kold Olesen Tine, Persson Bo-Eric, Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics, 10.1016/j.eururo.2009.11.029
  15. Axcrona, BJU Int (2013)